Skip to main content
. Author manuscript; available in PMC: 2014 Feb 3.
Published in final edited form as: Arthritis Rheum. 2011 Sep;63(9):2797–2808. doi: 10.1002/art.30438

Figure 1. Predictors of the CYC treatment effect at 18 months.

Figure 1

Baseline values for the (A) maximal severity of reticular changes on HRCT (MaxFIB score), (B) modified Rodnan skin score (mRSS) and (C) Mahler's baseline dyspnea index (BDI) were divided into clinically-relevant groups and plotted against the placebo (Plac)-adjusted treatment effect at 18 months (the change in %-predicted FVC from baseline to 18 months in the CYC arm minus the change observed in the same subset in the placebo arm). All of these baseline characteristics demonstrated a significant correlation with FVC outcome (p<0.05).